iX Biopharma Ltd. (SGX:42C)

Market Cap	103.99M
Revenue (ttm)	7.77M
Net Income (ttm)	-10.14M
Shares Out	888.84M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,658,700
Average Volume	20,589,880
Open	0.1220
Previous Close	0.1230
Day's Range	0.1170 - 0.1220
52-Week Range	0.0150 - 0.1360
Beta	0.31
RSI	75.51
Earnings Date	Nov 10, 2025

About iX Biopharma

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, and Australia. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; and Xativa, a sublingual cannabidiol wafer, as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, an...

• Industry: Pharmaceutical Preparations
• Founded: 2004
• Employees: 35
• Stock Exchange: Singapore Exchange - Catalist
• Ticker Symbol: 42C

Financial Performance

In 2025, iX Biopharma's revenue was 7.77 million, an increase of 30.34% compared to the previous year's 5.96 million. Losses were -10.14 million, -6.05% less than in 2024.